Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $46.43 and traded as high as $55.72. Xenon Pharmaceuticals shares last traded at $54.48, with a volume of 966,676 shares changing hands.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Wells Fargo & Company boosted their target price on shares of Xenon Pharmaceuticals from $49.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 10th. Wedbush decreased their price target on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. Wolfe Research assumed coverage on Xenon Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $71.88.

Xenon Pharmaceuticals Trading Down 1.9%

The stock has a market capitalization of $4.53 billion, a P/E ratio of -12.50 and a beta of 0.91. The business’s fifty day simple moving average is $46.43 and its two-hundred day simple moving average is $43.03.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the prior year, the company posted ($0.84) EPS. On average, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Andrea Difabio sold 1,342 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the transaction, the insider owned 7,301 shares of the company’s stock, valued at $403,234.23. This represents a 15.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ian Mortimer sold 7,308 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $403,620.84. Following the completion of the sale, the chief executive officer owned 19,923 shares of the company’s stock, valued at $1,100,347.29. This represents a 26.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 336,707 shares of company stock worth $19,622,565. Company insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently bought and sold shares of XENE. Avoro Capital Advisors LLC increased its holdings in Xenon Pharmaceuticals by 0.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after buying an additional 24,444 shares during the period. Janus Henderson Group PLC boosted its position in shares of Xenon Pharmaceuticals by 3.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock valued at $183,110,000 after acquiring an additional 140,149 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Xenon Pharmaceuticals by 66.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Braidwell LP increased its stake in Xenon Pharmaceuticals by 33.0% in the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after acquiring an additional 895,154 shares during the period. Finally, Capital International Investors raised its position in Xenon Pharmaceuticals by 7.3% in the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock worth $153,058,000 after purchasing an additional 233,466 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.